Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 3
2008 1
2009 1
2010 3
2011 2
2012 1
2013 2
2014 2
2015 3
2016 9
2017 5
2018 2
2019 4
2020 6
2021 6
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
miR-203 drives breast cancer cell differentiation.
Martínez-Illescas NG, Leal S, González P, Graña-Castro O, Muñoz-Oliveira JJ, Cortés-Peña A, Gómez-Gil M, Vega Z, Neva V, Romero A, Quintela-Fandino M, Ciruelos E, Sanz C, Aragón S, Sotolongo L, Jiménez S, Caleiras E, Mulero F, Sánchez C, Malumbres M, Salazar-Roa M. Martínez-Illescas NG, et al. Among authors: quintela fandino m. Breast Cancer Res. 2023 Aug 4;25(1):91. doi: 10.1186/s13058-023-01690-9. Breast Cancer Res. 2023. PMID: 37542268 Free PMC article.
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Provenzano E, et al. Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24. Mod Pathol. 2015. PMID: 26205180 Free article.
Mitochondrial Inhibition: a Treatment Strategy in Cancer?
Bueno MJ, Ruiz-Sepulveda JL, Quintela-Fandino M. Bueno MJ, et al. Among authors: quintela fandino m. Curr Oncol Rep. 2021 Mar 17;23(4):49. doi: 10.1007/s11912-021-01033-x. Curr Oncol Rep. 2021. PMID: 33730242 Review.
A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.
Zhu L, Retana D, García-Gómez P, Álvaro-Espinosa L, Priego N, Masmudi-Martín M, Yebra N, Miarka L, Hernández-Encinas E, Blanco-Aparicio C, Martínez S, Sobrino C, Ajenjo N, Artiga MJ, Ortega-Paino E, Torres-Ruiz R, Rodríguez-Perales S; RENACER; Soffietti R, Bertero L, Cassoni P, Weiss T, Muñoz J, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Laín A, Toldos O, Ruano Y, Alcázar L, Blasco G, Fernández-Alén J, Caleiras E, Lafarga M, Megías D, Graña-Castro O, Nör C, Taylor MD, Young LS, Varešlija D, Cosgrove N, Couch FJ, Cussó L, Desco M, Mouron S, Quintela-Fandino M, Weller M, Pastor J, Valiente M. Zhu L, et al. Among authors: quintela fandino m. EMBO Mol Med. 2022 Mar 7;14(3):e14552. doi: 10.15252/emmm.202114552. Epub 2022 Feb 17. EMBO Mol Med. 2022. PMID: 35174975 Free PMC article.
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.
Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Ximénez-Embún P, Muñoz J, Gonzalez-Cortijo L, Murillo R, Sánchez-Bayona R, Cejalvo JM, Gómez-López G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M. Mouron S, et al. Among authors: quintela fandino m. Nat Commun. 2022 Dec 7;13(1):7529. doi: 10.1038/s41467-022-35065-z. Nat Commun. 2022. PMID: 36477027 Free PMC article.
RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.
Ciscar M, Trinidad EM, Perez-Chacon G, Alsaleem M, Jimenez M, Jimenez-Santos MJ, Perez-Montoyo H, Sanz-Moreno A, Vethencourt A, Toss M, Petit A, Soler-Monso MT, Lopez V, Gomez-Miragaya J, Gomez-Aleza C, Dobrolecki LE, Lewis MT, Bruna A, Mouron S, Quintela-Fandino M, Al-Shahrour F, Martinez-Aranda A, Sierra A, Green AR, Rakha E, Gonzalez-Suarez E. Ciscar M, et al. Among authors: quintela fandino m. EMBO Mol Med. 2023 Apr 11;15(4):e16715. doi: 10.15252/emmm.202216715. Epub 2023 Mar 7. EMBO Mol Med. 2023. PMID: 36880458 Free PMC article.
When should we order a next generation sequencing test in a patient with cancer?
Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M. Colomer R, et al. Among authors: quintela fandino m. EClinicalMedicine. 2020 Jul 31;25:100487. doi: 10.1016/j.eclinm.2020.100487. eCollection 2020 Aug. EClinicalMedicine. 2020. PMID: 32775973 Free PMC article. Review.
55 results